World Journal of Pharmaceutical Science and Research

www.wjpsronline.com

Review Article

ISSN: 2583-6579
SJIF Impact Factor: 6.916
Year - 2026
Volume: 5; Issue: 7
Page: 484-494

DIGITAL TWINS IN PHARMACEUTICAL MANUFACTURING AND QUALITY ASSURANCE: APPLICATIONS, BENEFITS, CHALLENGES, AND FUTURE PERSPECTIVES

Gayatri Chandrakant Shelake*[1], Ashitosha Somnath Chavan[2], Keshav Shahaji Pawar[3], Dr. Swati D. Burungale[4], Dr. Rajendra N. Patil[5]

[1,2,3]Student, Department of Pharmaceutical Quality Assurance, Delonix Society's Baramati College of Pharmacy, Barhanpur, Maharashtra, India.

[4]Head, Department of Pharmaceutical Quality Assurance, Delonix Society's Baramati College of Pharmacy, Barhanpur, Maharashtra, India.

[5]Principal, Delonix Society's Baramati College of Pharmacy, Barhanpur, Maharashtra, India.

Article Received: 25 May 2026 | | ***Article Revised: 15 June 2026*** | | ***Article Accepted: 06 July 2026***

***Corresponding Author: Gayatri Chandrakant Shelake**
Student, Department of Pharmaceutical Quality Assurance, Delonix Society's Baramati College of Pharmacy, Barhanpur, Maharashtra, India.
DOI: https://doi.org/10.5281/zenodo.21371026

How to cite this Article: Gayatri Chandrakant Shelake, Ashitosha Somnath Chavan, Keshav Shahaji Pawar, Dr. Swati D. Burungale, Dr. Rajendra N. Patil (2026) DIGITAL TWINS IN PHARMACEUTICAL MANUFACTURING AND QUALITY ASSURANCE: APPLICATIONS, BENEFITS, CHALLENGES, AND FUTURE PERSPECTIVES. World Journal of Pharmaceutical Science and Research, 5(7), 484-494.

Copyright © 2026 Gayatri Chandrakant Shelake | World Journal of Pharmaceutical Science and Research.
This work is licensed under creative Commons Attribution-NonCommercial 4.0 International license (CC BY-NC 4.0).

ABSTRACT

The pharmaceutical industry is undergoing a digital transformation through the adoption of Industry 4.0 technologies. Among these innovations, Digital Twin (DT) technology has emerged as a powerful tool for improving manufacturing efficiency, product quality, and regulatory compliance. A digital twin is a virtual representation of a physical system that continuously receives and analyzes real-time data from manufacturing processes. In pharmaceutical manufacturing, digital twins enable process simulation, predictive maintenance, quality monitoring, risk assessment, and process optimization. This review discusses the concept, architecture, applications, benefits, challenges, and future prospects of digital twins in pharmaceutical manufacturing and quality assurance.

KEYWORDS: Digital twin technology, pharmaceutical manufacturing, quality by design (QBD), process analytical technology (PAT), Quality Assurance.

INTRODUCTION

The pharmaceutical industry is one of the most tightly regulated sectors due to the essential requirement for product safety, effectiveness, and quality. Conventional manufacturing processes in this field typically depend on batch

production and final product testing. This reliance can result in inefficiencies and delays in identifying any deviations from established processes. However, with the advent of Industry technologies, pharmaceutical companies are increasingly incorporating digital solutions to enhance the monitoring and control of their processes, as well as improve product quality. The goal of digital transformation in pharmaceutical manufacturing is to Smoothly integrate advanced analytics, automation, and real-time monitoring systems to boost manufacturing efficiency while ensuring compliance with regulatory standards.[1] Digital twin technology has emerged as a vital element in the digital transformation of the pharmaceutical sector. A digital twin refers to a dynamic virtual model designed to mirror the behavior and performance of a physical system. It achieves this by continuously receiving real-time data from sensors and monitoring devices. This innovative technology Enables the Replication prediction, and optimization of manufacturing processes, all while ensuring that actual production operations remain uninterrupted Competitive markets today demand the use of new digital technologies to promote innovation, improve productivity, and increase profitability.[1]

The idea of Industry 4.0 has been put forward by the community of practice to achieve a higher level of automation for increased operational efficiency and productivity. Smart technologies under the umbrella of Industry 4.0, such as the development of the IoT, big data analytics (BDA), cyber-physical systems (CPS), and cloud computing (CC) are playing critical roles in stimulating the transformation of current manufacturing to smart manufacturing.[2] Digital twins transform quality assurance (QA) by enabling proactive, real-time defect prediction and process optimization. Instead of relying on reactive post-production inspections, manufacturers use virtual replicas to simulate production lifecycles, run stress tests, and continuously synchronize physical shop-floor data with virtual models to prevent quality failures. The quality assurance representing virtual counterparts of physical assets, processes, or systems, have emerged as a transformative force in modern industries, offering unparalleled opportunities for efficiency enhancement and innovation. However, their widespread adoption faces significant challenges, including technological complexities and regulatory hurdles. To fully harness their potential, standardized quality assurance approaches are crucial.[3]

Regulatory compliance is a critical aspect of pharmaceutical manufacturing, and digital twin technology supports compliance by enhancing process transparency and traceability. Regulatory authorities such as the U.S. Food and Drug Administration and the European Medicines Agency encourage the adoption of advanced manufacturing technologies that improve process understanding and product quality.[4]

Concept of Digital Twin

Digital twins were first employed in the manufacturing and aerospace industries to predict operational faults and replicate the behaviour of complex systems. Because of its ability to combine real-time data with predictive models, this technology has recently gained traction in the pharmaceutical production and healthcare industries.[5]

The physical system, the virtual model, data connection, analytics layer and the communication interface that connects them are the three fundamental components of a digital twin system. Manufacturing machinery, sensors, and control systems that generate operational data make up the physical system. The analytics layeris used in AI, machine learning, stastical analysis. The virtual model uses machine learning techniques, replication algorithms, and mathematical models to reflect the actual system. Real-time, accurate reproduction of system behaviour is made possible by constant data flow between the digital and physical components.[5,6]

Digital twin technology can be categorized into different types depending on the level of system representation:

a. A component digital twin focuses on individual parts of a system, such as a specific piece of manufacturing equipment.
b. A product digital twin represents the complete product lifecycle, including design, development, and production stages.
c. A process digital twin models the entire manufacturing process, enabling optimization of process parameters and operational conditions.
d. A system digital twin integrates multiple processes and components to provide a comprehensive view of the entire manufacturing facility. These different levels of digital twins help organizations analyze and optimize operations at both micro and macro levels.[7,8]

Digital Twin Architecture

Digital twin architecture is a multi-layered technical framework designed to ensure seamless data bidirectionality between physical assets and virtual models. An enterprise-grade architecture typically includes:

1. Physical Asset Layer (The Data Source)

The foundation consisting of physical hardware, industrial machines, or infrastructure embedded with IoT sensors and actuators that capture real-time operational state.

2. Data Ingestion & Connectivity Layer

Responsible for the secure transmission of high-frequency data. It utilizes messaging protocols like MQTT, OPC UA, or Apache Kafka to stream telemetry into the digital ecosystem.

3. The Digital Thread (Integration Layer)

A critical communication framework that weaves data across the product lifecycle, connecting the twin to enterprise systems like ERP (SAP/Oracle), PLM, and CRM.

4. Data Storage & Management Layer

Employs a combination of Time-Series Databases (Influx DB) and Data Lakes (Snowflake/Databricks) to store both historical trends and real-time streams.

5. Modeling & Simulation Layer

The “brain” of the twin, using Physics-Based Models and 3D Geometric Representations to replicate asset dynamics with high fidelity.

6. AI & Analytics Layer

This is where Machine Learning models detect anomalies, run predictive simulations, and generate optimization recommendations.

7. Synchronization & Actuation Layer

The “Closed-Loop” mechanism. It ensures the virtual model stays in sync with the physical world and sends commands back to the physical actuators when an optimization is triggered.

8. Visualization & Experience Layer

High-fidelity interfaces, including 3D Dashboards, AR/VR overlays, and Spatial Computing, allowing human operators to interact with the twin.[9,10]

Application in Pharmaceutical Manufacturing

1. Process Optimization

Digital twins are increasingly being used in pharmaceutical manufacturing to improve and optimize production processes. They create a virtual representation of the manufacturing system. This allows researchers and engineers to study how different process parameters influence the final product. Using this approach, manufacturers can examine the relationship between process parameters and critical quality attributes of the product. Important parameters such as temperature, pressure, mixing speed, and flow rate can be analysed in detail. Understanding these relationships helps in maintaining consistent product quality. Digital twins also allow scientists to perform virtual experiments. These experiments can be carried out without interrupting the actual manufacturing process. By testing different operating conditions in the virtual environment, manufacturers can identify the most suitable process settings. As a result, the manufacturing process can be optimized more efficiently. This often leads to higher product yield and better process stability. It also helps reduce variability in production and supports more consistent product quality. In addition, early identification of potential process issues allows manufacturers to take corrective actions before problems occur.[11]

2. Predictive Maintenance

Digital twins use equipment performance data to evaluate machine operation and predict possible failures. This helps pharmaceutical manufacturers detect issues before they occur. By applying predictive maintenance strategies, manufacturing facilities can reduce unexpected downtime and extend the lifespan of their equipment. This also improves overall operational efficiency. Sensors continuously monitor important parameters such as temperature, vibration, and pressure. The collected data is analysed to detect early signs of wear or malfunction. By identifying potential problems in advance, companies can schedule maintenance proactively. This reduces the risk of sudden breakdowns and helps maintain consistent production quality.[12,13]

3. Process Validation

Digital twins improve the validation of pharmaceutical processes. They allow manufacturers to evaluate manufacturing methods in a virtual environment. Different operating conditions can be tested without affecting the actual production process. This approach reduces the needs for extensive physical experiments. It also helps speed up the overall validation process. Digital twins allow manufacturers to simulate different production scenarios. This helps identify possible risks before real manufacturing begins. They also help in understanding how critical process parameters affect product quality. By analysing these virtual experiments, manufacturers can establish a reliable design space. This supports consistent and stable process performance during production.[14]

4. Operator Training

Provides virtual training environments for manufacturing personnel.[15]

5. Process Development

Digital twins simulate manufacturing processes before actual or real time production for reduced experimental trials, fast production development and cost reduction.[15]

Role in Quality Assurance

1. Real-Time Quality Monitoring

Digital twins continuously evaluate process conditions and product quality attributes. By integrating Internet of Things (IoT) sensor streams with virtual models, QA teams can instantly track critical parameters rather than waiting for end-of-line tests.[16]

2. Deviation Prevention

Potential deviations and defects can be identified before they affect final product quality. Virtual simulations flag inconsistencies early, allowing operators to make corrective parameter adjustments in real time.[16]

3. Risk Management

Supports Quality Risk Management (QRM) through predictive analytics. The technology allows virtual stress-testing of different manufacturing scenarios to map and mitigate potential failure points before physical implementation.[16]

4. Data Integrity

Enhances traceability and documentation of manufacturing data. Centralized digital platforms automatically record every process state, reducing manual batch record errors and providing robust, tamper-proof logs.[16]

5. Regulatory Compliance

Supports Good Manufacturing Practice (GMP) compliance through continuous monitoring and documentation. Automated, data-driven evidence aligns naturally with lifecycle process validation frameworks and guidelines set by regulatory authorities.[17,18]

Integration with Pharmaceutical Quality Systems

Digital twin can be integrated for the:

1. Quality by Design (QbD)

QbD is a systematic approach to pharmaceutical development that emphasizes designing quality into processes from the outset. ML supports QbD by identifying critical process variables and optimizing them.[16,19]

2. Real-Time Release Testing (RTRT)

RTRT allows batch release based on real-time data rather than traditional end-product testing. AI-driven models can predict product quality during the manufacturing process, supporting RTRT adoption.[20]

3. Process Analytical Technology (PAT)

PAT is a system for designing, analyzing, and controlling pharmaceutical manufacturing through timely measurements of critical quality and performance attributes. ML can be integrated with PAT to enable continuous process monitoring and real-time decision making.[21]

4. Corrective and Preventive Action (CAPA)

AI tools can assist in root cause analysis (RCA) by identifying patterns in deviations, out of specification (OOS) events, and complaints. ML algorithms prioritize corrective and preventive actions (CAPA) based on historical effectiveness.[1,14]

Outcomes

- Shorter investigation times
- More effective corrective actions
- Reduced recurrence of deviation

Change Control Systems

Before implementing physical changes to equipment or processes, manufacturers can use digital twins to test the impact of those changes virtually, streamlining regulatory submissions and risk assessments.[22]

Pharmaceutical Quality Systems (ICH Q10)

Integrating digital twins with ICH Q10 ensures a harmonized approach to lifecycle management, reinforcing knowledge management and continuous improvement.[23]

Continuous Process Verification (CPV)

Digital twins facilitate Continuous Process Verification by continuously monitoring critical process parameters and critical quality attributes, enabling real-time assessment of process performance and ensuring that manufacturing processes remain in a state of control.[24]

Benefits of Digital Twins

Digital twins offer a wide range of benefits that directly impact the efficiency, productivity, and profitability of companies. Among them:

1. Improved Productivity

Digital twins allow for the optimization of processes and operations by providing a clear and real-time view of physical systems. This facilitates the identification of inefficiencies and the implementation of continuous improvements.[2,26]

2. Reduced Downtime

By predicting potential failures and enabling predictive maintenance, digital twins minimize the downtime of machines and equipment. This results in longer operating times and reduced economic losses.[26]

3. Supply Chain Optimization

By offering a comprehensive and detailed view of each stage of the process, digital twins enable better inventory management, logistics optimization, and reduced delivery times.[25]

4. Improved Quality

Through continuous simulations and analyses, digital twins help detect and correct quality issues before they become costly failures. This ensures more reliable final products with fewer defects.[25]

5. Business Model Innovation

Digital twins enable the monetization of data and digital services, opening new business opportunities and revenue streams, such as subscription-based services or proactive maintenance.[2]

6. Enhanced Decision-Making

By integrating predictive analysis and simulations, digital twins provide valuable information for strategic decision-making. Companies can evaluate different scenarios and make decisions based on precise and up-to-date data.[2,25]

7. Greater Sustainability

Digital twins contribute to reducing resource waste, improving energy efficiency, and optimizing material use, thereby supporting sustainability and environmental responsibility goals.[27]

8. Real-Time Regulatory Compliance

Digital twins allow for real-time monitoring of compliance with health, safety, and environmental regulations, ensuring that operations meet required standards without interruptions. Together, these benefits make digital twins an essential tool for companies looking to remain competitive, innovative, and sustainable in an ever-evolving industrial environment.[27,3]

Challenges and Limitations

Digital twin (DT) adoption offers powerful simulation capabilities but introduces distinct operational, technical, and governance hurdles.

1. High Implementation Costs

Hardware, software, and infrastructure investments are significant, which often delays widespread adoption.

Mitigation: Organizations frequently utilize incremental design or start with small-scale pilot projects to prove ROI before scaling their IBM Digital Twin initiative.[28]

2. Data Quality Issues

Accurate, reliable models require noise-free, high-fidelity data, as inconsistent or missing data can result in faulty simulations.

Mitigation*:* Deploy unified data platforms that consolidate information from IoT devices and enterprise systems to simplify integration.[2]

3. Cybersecurity Risks

Connected systems, IoT devices, and reciprocal data exchanges increase vulnerability to breaches and cyber threats.

Mitigation: Employ robust encryption, access control mechanisms, and continuous monitoring.[2]

4. Model Validation

Digital twin models require extensive validation to ensure the virtual representation consistently matches real-world counterparts.[29]

Mitigation: Compare model predictions with empirical, historical data and frequently test them in secure virtual environments.

5. Regulatory Acceptance

Global regulatory and compliance frameworks are still evolving to address the complexities of digital models and data governance.

Mitigation*:* Stay up to date with regional and industry-specific governance policies and utilize open standards to prevent proprietary vendor lock-in.[29]

6. Skilled Workforce Requirements

Implementing, calibrating, and maintaining these specialized models demands deep technical expertise in data analytics, AI, and IoT.

Mitigation: Partner with specialized technology vendors or heavily invest in workforce upskilling in IEEE Xplore Digital Twin.[2]

Future perspectives

Digital Twin technology is expected to play a major role in the future of pharmaceutical manufacturing. With the advancement of Artificial Intelligence (AI), Machine Learning (ML), Internet of Things (IoT), Big Data Analytics, and Pharma 4.0, digital twins will become more intelligent, predictive, and autonomous. Future pharmaceutical facilities will increasingly rely on digital twins to improve product quality, manufacturing efficiency, and regulatory compliance.[1]

1. AI-Powered Digital Twins

Future digital twins will be integrated with AI and Machine Learning algorithms to analyze large volumes of manufacturing data in real time. AI-powered digital twins will not only monitor processes but also predict deviations, equipment failures, and quality defects before they occur.[14]

Benefits

1. Predictive quality management
2. Automated root cause analysis
3. Improved decision-making
4. Reduction in batch failures
5. Enhanced process optimization

For example, an AI-enabled digital twin can predict variations in tablet hardness or dissolution profiles and recommend corrective actions before product quality is affected.

2. Autonomous Pharmaceutical Manufacturing

Digital twins will support fully autonomous manufacturing systems where production processes can self-monitor, self-adjust, and self-optimize with minimal human intervention.[9]

Benefits

1. Reduced human errors
2. Improved manufacturing consistency

3. Increased productivity
4. Lower operational costs
5. In autonomous manufacturing, digital twins continuously compare actual process performance with the virtual model and automatically adjust process parameters to maintain product quality.

3. Smart Factories and Pharma 4.0

Smart factories represent the next generation of pharmaceutical manufacturing facilities. Digital twins will serve as the central component of Pharma 4.0 by connecting equipment, sensors, manufacturing systems, and quality management systems.[1]

Key Features

1. Real-time monitoring
2. Automated process control
3. Integrated quality systems
4. Data-driven decision making
5. Remote process supervision
6. Smart factories will provide greater flexibility, efficiency, and transparency throughout the manufacturing lifecycle.

4. Real-Time Release Testing (RTRT)

Traditional quality control relies on end-product testing before batch release. In the future, digital twins integrated with Process Analytical Technology (PAT) will support Real-Time Release Testing.[20,21]

Benefits

1. Faster product release
2. Reduced laboratory testing
3. Continuous quality verification
4. Lower production delays

Digital twins can continuously monitor Critical Quality Attributes (CQAs) and Critical Process Parameters (CPPs), allowing products to be released based on process performance rather than only final testing.

5. Personalized Medicine Manufacturing

The demand for personalized medicines and patient-specific therapies is increasing rapidly. Digital twins will help manufacturers simulate and optimize individualized manufacturing processes.[30]

Applications

1. Personalized drug products
2. Cell and gene therapies
3. 3D-printed pharmaceuticals
4. Precision medicine
5. Digital twins can ensure that customized products meet predefined quality standards while maintaining regulatory compliance.

6. Advanced Quality Prediction Systems

Future digital twins will utilize advanced predictive models to forecast quality outcomes before manufacturing is completed.[14]

Benefits

1. Early risk identification
2. Improved Quality Risk Management (QRM)
3. Better CAPA effectiveness
4. Enhanced process understanding
5. Quality prediction systems will support proactive quality assurance rather than reactive quality control.

7. Regulatory and Quality Assurance Advancements

Regulatory agencies are increasingly encouraging data-driven and risk-based approaches.[27] Digital twins may become an essential tool for:

1. Continuous Process Verification (CPV)
2. Quality by Design (QbD)
3. Quality Risk Management (QRM)
4. Process Validation
5. Regulatory inspections Digital twins will provide comprehensive electronic records and traceability, improving compliance with GMP requirements

CONCLUSION

A revolutionary development in pharmaceutical production and quality control is digital twin technology. Digital twins provide real-time monitoring, predictive analytics, process optimisation, and proactive quality control by generating a virtual representation of industrial processes. The technology presents substantial prospects for enhancing product quality, operational efficiency, and regulatory compliance, despite ongoing installation, validation, and cybersecurity issues. Digital twins are anticipated to be crucial to smart pharmaceutical manufacturing in the future as pharmaceutical companies continue their digital transformation journey.

REFERENCES

1. Arden NS, Fisher AC, Tyner K, Yu LX, Lee SL, Kopcha M. Industry 4.0 for pharmaceutical manufacturing: Preparing for the smart factories of the future. *Int J Pharm*, 2021; 602: 120554. doi:10.1016/j.ijpharm.2021.120554.
2. Fuller A, Fan Z, Day C, Barlow C. Digital Twin: Enabling Technologies, Challenges and Open Research. *IEEE Access*, 2020; 8: 108952-71. doi:10.1109/ACCESS.2020.2998358.
3. Jones D, Snider C, Nassehi A, Yon J, Hicks B. Characterising the Digital Twin: A systematic literature review. *CIRP J Manuf Sci Technol*, 2020; 29: 36-52. doi:10.1016/j.cirpj.2020.02.002.
4. Lee SL, O'Connor TF, Yang X, Cruz CN, Chatterjee S, Madurawe RD, et al. Modernizing pharmaceutical manufacturing: from batch to continuous production. *J Pharm Innov*, 2015; 10(3): 191-199.
5. Tao F, Zhang H, Liu A, Nee AYC. Digital Twin in Industry: State-of-the-Art. *IEEE Trans Ind Inform*, 2019; 15(4): 2405-2415.

6. Jones D, Snider C, Nassehi A, Yon J, Hicks B. Characterising the Digital Twin: A systematic literature review. *CIRP J Manuf Sci Technol*, 2020; 29: 36-52.
7. Tao F, Qi Q. Make more digital twins. *Nature*, 2019; 573(7775): 490-491.
8. https://www.sciencedirect.com/science/article/pii/S1755581720300110?utm_source=chatgpt.com#bib0260
9. Fuller A, Fan Z, Day C, Barlow C. Digital Twin: Enabling Technologies, Challenges and Open Research. *IEEE Access*, 2020; 8: 108952-108971.
10. Jones D, Snider C, Nassehi A, Yon J, Hicks B. Characterising the Digital Twin: A systematic literature review. *CIRP J Manuf Sci Technol*, 2020; 29: 36-52.
11. Tao F, Qi Q, Liu A, Kusiak A. Data-driven smart manufacturing. *J Manuf Syst*, 2018; 48: 157-169.
12. Tao F, Zhang M, Liu Y, Nee AYC. Digital twin driven prognostics and health management for complex equipment. *CIRP Ann*, 2018; 67(1): 169-172.
13. Aivaliotis P, Georgoulias K, Chryssolouris G. The use of Digital Twin for predictive maintenance in manufacturing. *Int J Comput Integr Manuf*, 2019; 32(11): 1067-1080.
14. Nagy B, Galata DL, Farkas A, Nagy ZK. Application of artificial neural networks in the process analytical technology of pharmaceutical manufacturing: A review. *AAPS J*., 2022; 24(4): 74.
15. Negri E, Fumagalli L, Macchi M. A Review of the Roles of Digital Twin in CPS-based Production Systems. *Procedia Manuf*, 2017; 11: 939-948.
16. Jones D, Snider C, Nassehi A, Yon J, Hicks B. Characterising the Digital Twin: A systematic literature review. *CIRP J Manuf Sci Technol*, 2020; 29: 36-52.
17. International Council for Harmonisation. Q10 Pharmaceutical Quality System. Geneva: ICH, 2008.
18. U.S. Food and Drug Administration. Guidance for Industry: Process Validation: General Principles and Practices. Silver Spring (MD): FDA, 2011
19. International Council for Harmonisation. Q8(R2) Pharmaceutical Development. Geneva: ICH, 2009.
20. European Medicines Agency. Guideline on Real Time Release Testing (formerly Guideline on Parametric Release). London: EMA, 2012.
21. U.S. Food and Drug Administration. PAT—A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance. Guidance for Industry. Silver Spring (MD): FDA, 2004.
22. Fuller A, Fan Z, Day C, Barlow C. Digital Twin: Enabling Technologies, Challenges and Open Research. *IEEE Access*. 2020;8:108952-108971
23. International Council for Harmonisation. Q10 Pharmaceutical Quality System. Geneva: ICH, 2008.
24. Yu LX, Kopcha M. The future of pharmaceutical quality and the path to continuous manufacturing. *Int J Pharm*, 2017; 528(1-2): 1-4.
25. Jones D, Snider C, Nassehi A, Yon J, Hicks B. Characterising the Digital Twin: A systematic literature review. *CIRP J Manuf Sci Technol*, 2020; 29: 36-52
26. Tao F, Zhang H, Liu A, Nee AYC. Digital Twin in Industry: State-of-the-Art. *IEEE Trans Ind Inform*, 2019; 15(4): 2405-2415.
27. U.S. Food and Drug Administration. Guidance for Industry: Process Validation—General Principles and Practices. Silver Spring (MD): FDA, 2011.
28. Rasheed A, San O, Kvamsdal T. Digital Twin: Values, Challenges and Enablers from a Modeling Perspective. *IEEE Access*, 2020; 8: 21980-22012.